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Abstract 
Review on juvenile myelomonocytic leukemia, with 
data on clinics, pathology, and involved genes. 
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Identity 
Other names 
Juvenile chronic myelogenous leukemia (JCML); 
Juvenile chronic myelomonocytic leukemia 
Note 
This current topic of JMML does not include 
discussion on Ras-associated autoimmune  
leukoproliferative disorder (RALD), which is a 
nonmalignant disorder with myelomonocytic 
hyperplasia and somatic mutations in KRAS or 
NRAS, often showing clinical overlap with JMML 
(Calvo et al., 2015) 
Clinics and pathology 
Disease 
JMML is a chronic myeloproliferative disorder that 
typically affects young children: more than 95% of 
cases are diagnosed before age 4 
Phenotype/cell stem origin 
JMML arises from pluripotent hematopoietic stem  
cells (Cooper et al., 2000).  Clonal proliferations of 
myeloid, monocyte-macrophages, erythroid, and 
sometimes lymphoid progenitor cells are seen. 
Figure 1. A 21 month old boy presented with peripheral monocytosis, increased fetal hemoglobin.  His bone marrow aspirate 
showed <20% blasts.  Cytogenetics identified monosomy 7, and genetic testing identified a PTPN11 mutation.  This bone 
marrow core biopsy demonstrates a hypercellular marrow with decreased megakaryocytes. 
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Epidemiology 
The annual incidence of JMML is estimated to be 
roughly 0.67/million (Passmore et al, 2003).  The 
median age is 1.1-1.8 years with a male to female 
ratio of 2-3:1. (Hasle et al., 1999; Niemeyer et al., 
1997; Passmore et al., 2003). Those with 
neurofibromatosis type 1 (NF-1) have a 200-fold  
 
increased risk of JMML (Stiller et al., 1994) 
Clinics 
 Children with JMML commonly have 
splenomegaly, lymphadenopathy, and skin rashes 
(Hess et al., 1996). Involvement of the liver, lung, 
and GI tract can also occur. 
The diagnostic criteria for JMML are:  
Clinical and hematologic 
features (all 4 required) 
    
  
  Peripheral blood monocyte count ≥1 x 
109/L 
  
  
  Peripheral blood and bone marrow blast 
percentages <20% 
  
     
  
  No Philadelphia (Ph) chromosome or 
BCR-ABL1 fusion 
  
Genetic criteria (1 finding is 
sufficient) 
    
  
  Somatic mutation in PTPN11 , KRAS, or 
NRAS  
  
  
  Clinical diagnosis of neurofibromastosis 
type 1 or NF1 mutation 
  
  
  Germline CBL mutation and loss of 
heterozygosity of CBL 
  
Other criteria*     
  
  Monosomy 7 or any other chromosomal 
abnormality 
  
or ≥  2 of the following:   
      Increased hemoglobin F (HbF) for age 
    
  Myeloid or erythroid precursors on peripheral blood 
smear 
    
  Granulocyte-macrophages colony-stimulating factor 
(GM-CSF) hypersensitivity in colony assay 
     
* (those not meeting genetic criteria but having clinical and hematologic criteria must also have).  
(Locatelli and Neimeyer, 2015; Baumann, et al., 2017) 
 
Cytology 
Typical peripheral blood findings include 
leukocytosis (usually less than 100 x 109/L) with 
variable degree of left shift, monocytosis, and 
thrombocytopenia. Nucleated red blood cells are 
often identified in the peripheral blood.  Myeloblasts 
average about 1-5% of total nucleated cells, and by 
definition, blasts account for <20% of cells. (Hess et 
al., 1996; Niemeyer et al., 1997) 
Pathology 
Bone marrow findings are not specific.  The marrow 
is usually hypercellular with a mildly increased M:E 
ratio (typically 3-5:1), dispersed erythroid elements, 
and decreased numbers of megakaryocytes. 
Dysplasia is usually not prominent.  Blasts are 
required to be less than 20%; monocytes are less 
prominent in the marrow than in the peripheral 
blood, and are usually enumerated at 5-10% (Hess et 
al., 1996; Niemeyer et al., 1997). 
Treatment 
Curative therapy involves an allogeneic 
hematopoietic stem cell transplant (HSCT).  
Locatelli and Neimeyer (2015) recommend swift 
HSCT for those with germline NF1 mutations, 
somatic PTPN11 mutations, somatic KRAS 
mutations, and most children with somatic NRAS 
mutations.  Most children with germline CBL 
mutations demonstrate spontaneous regression, 
though if there is disease progression, a HSCT 
should be considered.  In children with Noonan 
syndrome (germline mutations of PTPN11, KRAS, 
and/or NRAS), the disease may be transient, and 
hence one can consider a 'watch and wait' scenario, 
with mild cytoreductive therapy for symptoms, 
usually 6-mercaptopruine.  
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In the rare patients with tyrosine kinase fusions, 
ALK/ROS1 inhibitors, such as crizotinib, may be 
beneficial (Murakami et al., 2018). 
Evolution 
As stated above, those with Noonan syndrome with 
germline mutations in PTPN11, KRAS, and/or 
NRAS as well as those with germline CBL mutations 
have disease that may spontaneously regress without 
therapy (Locatelli and Neimeyer, 2015).  However, 
in other cases, in those who did not receive an 
allogeneic hematopoietic stem cell transplant 
(HSCT), the median survival after diagnosis is <12 
months (Niemeyer et al., 1997).  In those who 
receive HSCT, the 5-year overall survival rate is 
64%, with an event free survival of 52% (Locatelli 
et a., 2005).  The 5-year cumulative incidence of 
relapse is 35%, while the 5-year cumulative 
incidence of transplantation-related mortality is 13% 
(Locatelli et al., 2005) 
Prognosis 
High risk features include older age (>1.4-4 years), 
PTPN11 mutation, monosomy 7, HbF >40%, low 
platelets (20% bone marrow blasts (Dvorak and Loh, 
2014; Locatelli et al., 2005; Niemeyer et al., 1997; 
Novitzky et al., 2000; Passmore et al., 2003).  In 
genetic studies, patients with <2 somatic alterations 
have improved outcomes compared to those with ≥2 
alterations (Stiegliz et al., 2015).  DNA methylation 
studies have also been done, showing three clusters 
of methylation in JMML; those with the highest 
levels of methylation have been found to have poorer 
clinical outcomes (Lipka et al., 2017; Stieglitz et al., 
2017). 
Genetics 
Note 
Approximately 85-90% of children with JMML have 
identified mutations, either germline and/or somatic.  
Somatic, gain-of-function mutations occur in 
PTPN11, KRAS, and NRAS, in 35-38%, 18%, and 
14% of cases respectively.  NF1 germline mutations 
with acquired loss of the normal allele are seen in 5-
15% of patients, and CBL germline mutations with 
acquired loss of the normal allele and duplication of 
the mutant allele (acquired uniparental disomy) are 
seen in 9-18% of patients.  (Chan et al., 2009; 
Niemeyer and Flotho, 2019).  Rare cases without any 
of the above mutations have been found to harbor 
RRAS or RRAS2 somatic mutations (Stieglitz et al., 
2015).  
Secondary mutations in SETBP1, JAK3, ASXL1, 
and SH2B3 are also identified and are often 
subclonal.  Additional mutations in the RAS 
pathway genes are also sometimes detected, coined 
'Ras double mutants' (Caye et al., 2015; Stieglitz et 
al., 2015).  
A recent study reported receptor tyrosine kinase 
fusions (DCTN1 /ALK, RANBP2 /ALK, and 
TBL1XR1 / ROS1) in patients without identified 
RAS pathway mutations (Murakami et al., 2018). 
Cytogenetics 
Normal karyotypes are present in most cases of 
JMML (~68%). Another 16-25% of cases have 
monosomy 7 or deletion 7q (Aricò et al, 1997; 
Niemeyer et al., 1997). 
Genes involved and 
proteins 
CBL 
Location 11q23.3 
Note 
There is a high rate of spontaneous resolution of 
disease without stem cell transplant in those with 
homozygous mutations including a germline 
mutation (Chang et al., 2014). 
DNA/RNA 16 exons. 
Protein 
This oncogene encodes a RING finger E3 ubiquitin 
ligase which marks activated receptor and 
nonreceptor tyrosine kinases and other proteins for 
degradation by ubiquitination.   
Homozygous mutations lead to continuous 
activation of RAS.  (Chang et al., 2014). 
Germinal mutations 
Germline heterozygous mutations (autosomal 
dominant) lead to a Noonan syndrome-like disorder.  
The most common mutation is c.1111T>C (Y371H); 
other common mutations are missense mutations in 
exons 8 and 9 or in introns 7 or 8 (Loh et al., 2009). 
Somatic mutations 
Loss of wild-type allele with duplication of mutant 
allele. 
KRAS 
Location 12p12.1 
Note 
Somatic mutations also occur in RALD (Ras-
associated lymphoproliferative disease). 
DNA/RNA 6 exons. 
Protein 
A Ras oncogene which encodes a member of the 
small GTPase superfamily.  Mutations lead to 
activation. 
Germinal mutations 
Germline heterozygous mutations (autosomal 
dominant) lead to Noonan syndrome. 
Somatic mutations 
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Somatic mutations are usually point mutations at 
codons G12, G13, and Q61 (exons 2 and 3) leading 
to amino acid substitutions (Chan et al., 2009; Chang 
et al., 2014). 
NF1 (neurofibromin 1) 
Location 17q11.2 
DNA/RNA 57-58 exons (depending on transcript 
variant). 
 
Protein 
GTPase activating protein for Ras.  Normally acts as 
tumor suppressor by inhibiting Ras signaling 
Germinal mutations 
Germline mutations cause neurofibromatosis type 1 
(NF1) characterized by café-au-lait spots, Lisch 
nodules, neurofibromas, optic pathway gliomas. 
Somatic mutations 
Somatic mutations are usually deletions leading to 
loss of heterozygosity with duplication of the 
mutated germline allele. 
NRAS 
Location 1p13.2 
Note 
Somatic mutations also occur in RALD (Ras-
associated lymphoproliferative disease). 
DNA/RNA 7 exons. 
Protein 
A Ras oncogene which encodes a membrane protein 
with intrinsic GTPase activity that shuttles between 
the Golgi apparatus and the plasma membrane. 
Germinal mutations 
Germline heterozygous mutations (autosomal 
dominant) lead to Noonan syndrome. 
Somatic mutations 
Somatic mutations are usually point mutations at 
codons G12, G13, and Q61 (exons 2 and 3) leading 
to amino acid substitutions (Chan et al., 2009; Chang 
et al., 2014). 
PTPN11 
Location 12q24.13 
DNA/RNA 16 exons 
Protein 
A member of the protein tyrosine phosphatase 
family which relays signals from activated GM-CSF 
receptor complexes, regulating proliferation, 
differentiation, and migration. 
Germinal mutations 
Germline mutations (autosomal dominant) lead to 
Noonan syndrome, usually within exons 3, 4, and 13. 
Somatic mutations 
Somatic mutations usually involve exons 3, 4, and 
13, with most common mutations being: c.226G>A 
(E76K), c.214G>A, c.227A>G, c.1508G>C. (Chan 
et al., 2009; Chang et al., 2014). 
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